Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Infinity Pharmaceuti (INFI)

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 188,086
  • Shares Outstanding, K 88,720
  • Annual Sales, $ 1,720 K
  • Annual Income, $ -40,490 K
  • 60-Month Beta 2.18
  • Price/Sales 120.25
  • Price/Cash Flow N/A
  • Price/Book 4.98
Trade INFI with:

Options Overview

Details
  • Implied Volatility 149.42%
  • Historical Volatility 227.44%
  • IV Percentile 35%
  • IV Rank 10.40%
  • IV High 700.94% on 11/04/20
  • IV Low 85.43% on 05/25/21
  • Put/Call Vol Ratio 0.22
  • Today's Volume 7,717
  • Volume Avg (30-Day) 3,656
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 26,721
  • Open Int (30-Day) 22,481

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.15
  • Number of Estimates 5
  • High Estimate -0.13
  • Low Estimate -0.16
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.48 +43.24%
on 07/27/21
3.05 -30.49%
on 07/01/21
-0.87 (-29.10%)
since 06/30/21
3-Month
1.48 +43.24%
on 07/27/21
3.72 -43.01%
on 06/09/21
-1.21 (-36.34%)
since 04/30/21
52-Week
0.87 +143.71%
on 07/31/20
5.98 -64.55%
on 02/11/21
+1.29 (+155.98%)
since 07/30/20

Most Recent Stories

More News
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 0.00% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

INFI : 2.12 (-9.01%)
Infinity: Q2 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Tuesday reported a loss of $11.3 million in its second quarter.

INFI : 2.12 (-9.01%)
Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)

--- MARIO-3 TNBC early data suggest the addition of eganelisib to standard of care regimens extends progression free survival regardless of PD-L1 status with majority of patients still on treatment -

INFI : 2.12 (-9.01%)
Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update

--- Increases seen in overall survival in 2L urothelial cancer (UC) and in progression free survival in 1L triple negative breast cancer (TNBC), in both cases regardless of PD-L1 status -

INFI : 2.12 (-9.01%)
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INFI : 2.12 (-9.01%)
Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials

--- MARIO-275 Phase 2 study evaluating the addition of eganelisib to standard of care Opdivo(R) in metastatic 2L urothelial cancer (UC)-

INFI : 2.12 (-9.01%)
Infinity to Present at The Keystone Symposia Precision Oncology Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which...

INFI : 2.12 (-9.01%)
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

INFI : 2.12 (-9.01%)
Infinity: Q1 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Thursday reported a loss of $11.6 million in its first quarter.

INFI : 2.12 (-9.01%)
Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update

---Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year-

INFI : 2.12 (-9.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

3rd Resistance Point 2.69
2nd Resistance Point 2.57
1st Resistance Point 2.35
Last Price 2.12
1st Support Level 2.00
2nd Support Level 1.87
3rd Support Level 1.65

See More

52-Week High 5.98
Fibonacci 61.8% 4.03
Fibonacci 50% 3.42
Fibonacci 38.2% 2.82
Last Price 2.12
52-Week Low 0.87

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar